Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line
chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable
efficacy and a favourable toxicity profile that warrants further comparative study. A
parallel group of randomly selected patients of equal number to the carboplatin and
gemcitabine combination arm will be treated with the cisplatin and 5-FU combination
chemotherapy (active control arm).
The hypothesis is that this combination of chemotherapy is at least as active and less toxic
than the reference regimen of cisplatin in combination with 5-fluorouracil (5-FU).